Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review

Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review

Background and objective In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently report...

Full description

Bibliographic Details
Main Authors:	Qiaoxi QIN, Jiajin WANG, Hong WANG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-09-01
Series:	Chinese Journal of Lung Cancer
Subjects:	immune checkpoint inhibitors lung neoplasms immune-related adverse events meta-analysis
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.07

Similar Items

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis
by: Boris Shulgin, et al.
Published: (2020-01-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
by: Yong Fan, et al.
Published: (2021-04-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
by: Donghui Wang, et al.
Published: (2021-03-01)

Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
by: Jun NI, et al.
Published: (2021-03-01)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
by: Yang Ge, et al.
Published: (2021-07-01)

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study
by: Liz Jamieson, et al.
Published: (2020-08-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
by: Xiaoxiang Zhou, et al.
Published: (2020-04-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Management of immune-related adverse events in patients treated with immune checkpoint inhibitors– Rheumatology point of view
by: Ho Cheuk Man, et al.
Published: (2018-12-01)

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Xiaolin Yu, et al.
Published: (2021-02-01)

Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy
by: Xinyi Huang, et al.
Published: (2021-05-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Lijun Da, et al.
Published: (2020-01-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis
by: Ya-fang Huang, et al.
Published: (2020-10-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events
by: Bei Tan, et al.
Published: (2021-06-01)

Immune-Related Adverse Events: A Case-Based Approach
by: Caoilfhionn Connolly, et al.
Published: (2019-06-01)

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
by: Iivanainen, S., et al.
Published: (2022)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
by: N. Shah, et al.
Published: (2019-09-01)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
by: Lea Daniello, et al.
Published: (2021-06-01)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
by: Lin Zhou, et al.
Published: (2021-08-01)